PT - JOURNAL ARTICLE AU - Scuccimarri, Rosie AU - Sutton, Evelyn AU - Fitzcharles, Mary-Ann TI - Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic AID - 10.3899/jrheum.200369 DP - 2020 Apr 02 TA - The Journal of Rheumatology PG - jrheum.200369 4099 - http://www.jrheum.org/content/early/2020/04/01/jrheum.200369.short 4100 - http://www.jrheum.org/content/early/2020/04/01/jrheum.200369.full AB - Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19 [2, 3].